However, administration of a monoclonal anti-HMGB1 antibody (2G7), given prophylactically at a dose previously shown to confer protection in experimental sepsis models[8], did not improve survival or modulate peripheral levels of key inflammatory markers. Here, HMGB1 is linked to Sepsis.